You've just added:

Oxford-Harrington Rare Disease Centre Hosts Live Webinar for Rare Disease Day

Posted on February 08, 2022

Oxford-Harrington Rare Disease Centre is celebrating Rare Disease Day on Monday, February 28 at 10 a.m. EST with a Live Webinar: Advancing Novel Treatments for Neurological Rare Diseases. The webinar will feature a panel of experts discussing areas of unmet needs in Neurological Rare Diseases, Rare Cancers, and Rare Developmental Disorders.

Click here to register today!

Speakers include:

Richard Wade-Martins, MA, DPhil, Professor of Molecular Neuroscience, University of Oxford. Dr. Wade-Martins will speak about his research and target discovery related to Friedreich's ataxia, an inherited rare disorder that affects some of the body's nerves.

Haiyan Zhou, MD, PhD, Harrington Scholar, and Siew Ho, PhD, Harrington Advisor. Dr. Zhou and Dr. Ho will discuss Harrington Discovery Institute’s unique approach that brings critical funding to drug discovery, along with expert guidance and mentorship in the drug development process from advisors on Harrington’s Therapeutics Development Center (TDC). Dr. Zhou’s work focuses on a therapy with the potential to cure (HSN1), a debilitating disorder of peripheral nerve that results in sensory loss, neuropathic pain, varying degrees of limb weakness, and mutilating skin ulceration.

In addition, participants will hear from Mr. Rusty Cooper and his family. Mr. Cooper will share his personal experience of how he and his family support his grandson who has an ultra-rare neurological disease and how advancements from Harrington Discovery Institute have given them hope.

And, Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University, will speak about additional Harrington Scholars advancing treatments in Rare Disease supported by Harrington Discovery Institute. These scholars are focused on impacting the standard of care related to ALS (Amyotrophic Lateral Sclerosis), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, Rett Syndrome, a rare genetic mutation affecting brain development in girls, and other rare diseases without cures.

Transatlantic Partnership

Oxford-Harrington Rare Disease Centre is a partnership between Harrington Discovery Institute at University Hospitals and the University of Oxford in London, England. This collaboration was formed out of the need to advance critical medicines for the more than 7,000 rare diseases without treatments or cures.

Harrington Discovery Institute is dedicated to advancing the work of physician-scientists and to developing first-in-class medicines to improve patient’s lives. In the 10 years since Harrington Discovery was founded, 149 medicines-in-the-making have been advanced at 61 institutions across the United States, Canada and United Kingdom. In addition, 16 medicines have been advanced into clinical trials and 11 drugs are licensed to large pharmaceutical companies.

For more information on how to support the work at Harrington Discovery Institute, please contact Tyrone Gorden, Vice President of Global Development at Tyrone.Gorden@HarringtonDiscovery.org.

Oxford-Harrington Rare Disease Centre Hosts Live Webinar for Rare Disease Day

Download ohcrddinvite2022v4.jpg